Previous 10 | Next 10 |
The 23 businesses comprise 99% of the portfolio with the other 1% in cash, and the average total return over the Dow average for the 68-month test period is 56.91%. The portfolio's objective is to create a balanced portfolio that is not income, not dividend growth, not bottom fishing,...
30% of synthesized molecules have measured activity which meet potency targets Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has received the secon...
Chinese government institute to apply software to research model-informed drug development approaches for clinical pharmacology Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, ...
Simulations Plus's total return overperformed the Dow average for my 67-month test period by 308.05%, which is great, and the recent dip is a buying opportunity. Simulations Plus's three-year past CAGR of 18.5% is well above average and will give you great growth with the increasing n...
Shares of Simulations Plus are currently attractively priced for long term, growth oriented investors. With zero debt, growing earnings and close to $120 million of cash in the bank, the company's financial position has never been stronger in its history. Operating in the emerging...
Shares of Simulations Plus (NASDAQ: SLP) , a specialized software company that serves the biopharmaceutical industry, had fallen 14.3% as of 11:37 a.m. EDT on Tuesday. Investors were caught off guard by service-segment revenue that declined during the company's fiscal third quarter....
Gainers: Allied Healthcare Products (AHPI) +107%, SCWorx (WORX) +32%, Longboard Pharmaceuticals (LBPH) +18%, Dynatronics (DYNT) +14%, Shineco (TYHT) +13%.Losers: Meridian Bioscience (VIVO) -18%, Aridis Pharmaceuticals (ARDS) -17%, Simulat...
primeimages/E+ via Getty Images Earnings season is here. Several big-name stocks got a boost in Tuesday's pre-market action thanks to strong financial figures. PepsiCo (PEP) posted gains following its earnings report, while Nokia (NOK) jumped on strong guidance. Simulations Plus (SLP) moved t...
Simulations Plus (SLP) reports FQ3 results that miss revenue estimates.FQ3 highlights: Revenues increased 4% y/y to $12.8M vs. a consensus of $14.7 million.GAAP EPS was $0.18, in line with estimates.Gross profit was up 7% y/y to $10.3M; Gross margin increased from 78% to 81%.Cash and short-te...
Image source: The Motley Fool. Simulations Plus, inc (NASDAQ: SLP) Q3 2021 Earnings Call Jul 12, 2021 , 4:15 p.m. ET Operator Continue reading For further details see: Simulations Plus, inc (SLP) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...